Interventional, Open-label, Single- and Sequential-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic Profile of Lu AF28996 in Healthy Young Men
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Lu AF28996 (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 30 Aug 2019 Status changed from recruiting to completed.
- 27 Jun 2018 New trial record
- 20 Jun 2018 Status changed from planning to recruiting.